Home » Fast-Track Vaccine Improves Survival in Non-Hodgkin’s Lymphoma Patients
Fast-Track Vaccine Improves Survival in Non-Hodgkin’s Lymphoma Patients
Biovest International received favorable data from its Phase III, fast-tracked clinical trial of BiovaxID, a vaccine for the treatment of indolent follicular non-Hodgkin’s lymphoma, a potentially fatal blood cancer.
Results from the randomized, controlled trial show that patients’ overall median disease-free survival increased by more than one year. There also was a 100 percent improvement in disease-free-survival at three years.
The vaccine stimulates a person’s immune system to recognize and destroy cancerous B-cells. The company said BiovaxID may become the first anti-cancer vaccine approved in the U.S. or Europe.
Upcoming Events
-
07May
-
14May
-
30May